Skip to main content
Premium Trial:

Request an Annual Quote

Decode Genetics' Q3 Revenues Rise 10 Percent, Loss Narrows as Cash Dwindles

NEW YORK (GenomeWeb News) – Decode Genetics reported after the market closed on Thursday that its revenues increased 10 percent and its net loss dropped 26 percent in the third quarter as the firm reduced expenses to preserve its dwindling cash.
The Reykjavik, Iceland-based firm generated revenues of $12 million for the three-month period ended Sept. 30, compared to revenues of $10.9 million for the third quarter of 2007. The company noted that as of the end of the quarter it had $17.7 million in deferred revenue that will be recognized over future reporting periods.
Decode’s net loss fell to $17.9 million, or $.29 per share, from $24.2 million, or $.40 per share, as the firm cut its expenses. The loss includes non-operating expense of $2.9 million related to the revaluation of non-current auction rate security investments held by the firm.
Its R&D costs for the quarter dropped 60 percent to $5.7 million from $14.1 million, and its SG&A spending declined 6 percent to $6.7 million from $7.1 million.
Decode listed $35.5 million in cash and investments as of the end of the quarter, of which $11.8 million is liquid funds available to fund operating activities. The firm said that its third-quarter burn rate was $12 million.
“The company is undertaking a review of its long-term business strategy with the goal of sharpening the focus of its business, selling assets, securing partnerships, and utilizing the resources generated to support product development and marketing efforts in its core business,” Decode said in a statement.
Decode initially informed investors a few weeks ago that it was undertaking the review and would seek to sell non-core assets. In addition, it said that it had elected to utilize a 30-day grace period for the scheduled Oct. 15 interest payment on its outstanding 3.5 percent senior convertible notes due 2011, as it completes the review and considers the sale of those assets.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.